What do BioMarin do?

What do BioMarin do?

Established: BioMarin is a global biotechnology company that develops and commercialises innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases.

Is BioMarin a Biotech?

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. BioMarin’s core business and research is in enzyme replacement therapies (ERTs).

Where is BioMarin?

Our headquarters and original manufacturing facilities are located just north of San Francisco in Marin County. Located in downtown San Rafael, our corporate headquarters has a campus-like feel with multiple buildings joined by meandering green walkways with the San Francisco Bay and Mount Tamalpais in the background.

Is BioMarin a good place to work?

Is BioMarin Pharmaceutical a good company to work for? BioMarin Pharmaceutical has an overall rating of 4 out of 5, based on over 526 reviews left anonymously by employees. Employees also rated BioMarin Pharmaceutical 3.5 out of 5 for work life balance, 4 for culture and values and 3.6 for career opportunities.

What drugs does BioMarin make?

Our Products

  • VOXZOGO™ (vosoritide)
  • PALYNZIQ® (pegvaliase-pqpz) Injection.
  • Brineura® (cerliponase alfa)
  • Vimizim® (elosulfase alfa)
  • Kuvan® (sapropterin dihydrochloride)
  • Naglazyme® (galsulfase)
  • Aldurazyme® (laronidase)

Is BioMarin a good company to work for?

Is BioMarin Pharmaceutical a good company to work for? BioMarin Pharmaceutical has an overall rating of 4 out of 5, based on over 519 reviews left anonymously by employees. 78% of employees would recommend working at BioMarin Pharmaceutical to a friend and 68% have a positive outlook for the business.

What does the prefix glyco mean in biology?

glyco-. Prefix denoting a relationship to sugars (for example, glycogen) or to glycine (for example, glycocholate).

What is a Glykos antibody?

Glykos creates antibodies which utilize glycan targets and other glycan mediated technologies for improved targeting and efficacy. In the preclinical setting Glykos antibodies have demonstrated efficient targeting in vivo, efficient internalization and ability to regulate cell growth in vitro.

What is Glykos’s ADC technology?

Glykos utilizes its unique know-how on bioactive glycans in discovery and development of products and technologies with superior functionality Glykos’ ADC technology includes hydrophilic linker technology and cytotoxic drug derivatives which overcome several limitations of current ADC applications.

What does a biomedical science do?

Biomedical science staff mostly work in healthcare laboratories diagnosing diseases and evaluating the effectiveness of treatment by analysing fluids and tissue samples from patients. They provide the ‘engine room’ of modern medicine – 70% of diagnoses in the NHS are based on pathology results provided by laboratory services.